Symphogen turns year-long deficits into first profitable year following Servier acquisition

Symphogen, which was acquired by French Servier two years ago, has succeeded in ending the financial year 2020/2021 with a double-digit million-dollar net result, despite a string of deficits in recent years.

Photo: Symphogen

Biotech firm Symphogen, which French pharmaceutical company Servier bought back in 2020, can now finally present financial results in the black, following years of deficits.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs